secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theriva Biologics, Inc. (TOVX)
CIK:        0000894158
Form:       8-K
Filed at:   2025-12-29T23:59:59+00:00
Accession:  0001104659-25-124523
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EMA provides positive Scientific Advice on Theriva's Phase 3 trial design for VCN-01 in metastatic PDAC
--------------------------------------------------------------------------------

- EMA CHMP agreed on Phase 3 design for VCN-01 + gem/nab-paclitaxel vs SoC; primary endpoint overall survival.
- CHMP agreed on repeated dosing in macrocycles, enabling >2 doses; recognized VIRAGE survival benefit.
- Theriva plans End-of-Phase 2 meeting with FDA in H1 2026 to finalize multinational Phase 3 trial.
- Cash runway into Q1 2027 ($15.5M at Nov 10, 2025) supports regulatory activities and partnering.
- VCN-01 has Orphan Drug designation in EU/US, Fast Track in US, and Rare Pediatric Disease for retinoblastoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/894158/000110465925124523/0001104659-25-124523-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/894158/000110465925124523/tm2534356d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-124523

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer